BioViva is a platform to expedite the development of drugs and treatments that affect human healthspan. To achieve this goal BioViva has developed a comprehensive set of biomarkers of aging, which include molecular, physiological, anatomical, clinical, and qualitative markers. BioViva also collaborates with clinicians, biomedical scientists, and statisticians to develop innovative protocols for adaptive clinical trials for gene and cells therapies. Finally, BioViva has built a bioinformatics pipeline to analyze the data generated from the biomarkers of aging in human trials, and validate the treatments that are effective for treating the aging process.

BioViva has recently partnered with a paid-for clinical trial company Integrated Health Systems (IHS). IHS connects doctors with patients who want to take part in paid-for clinical trials. During our collaboration with IHS they will utilize our adaptive clinical trial protocols to conduct gene and cell therapy trials. All patients will undergo pre- and post testing using BioViva’s comprehensive biomarkers of aging platform. Treatment efficacy, and patient well being will be assessed using our bioinformatics pipeline…

The goal of BioViva is to accelerate the development of products that will effectively, and cost-efficiently treat biological aging. Our platform is designed to provide expedited and reliable feedback to our clinical and manufacturing partners, so that they may rapidly iterate their products and services to help patients improve the quality and quantity of life.

Summary: Cancer vaccines could prevent around 1,000,000 cancer deaths each year, according to a report by the World Health Organization this month. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

In a Feb 2018 report, the World Health Organization (WHO) estimates that infectious diseases cause 15% of all cancer deaths, and universal vaccination could prevent around one million cancers annually, saying.

“Cancer is the second leading cause of death globally, and was responsible for 8.8 million deaths in 2015.” Adding “Globally, nearly 1 in 6 deaths is due to cancer.”

Summary: Aging biomarkers found in a simple urine test can potentially measure how much our body has aged and could predict our future health. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

Determining our biological age and future risk of ill health may be as simple as a urine test one day.

In a new study, a team of researchers led by Jian-Ping Cai in the MOH Key Laboratory of Geriatrics at Beijing Hospital discovered two new aging biomarkers in urine that come from the oxidation of RNA and DNA. The new markers could potentially help predict our risk of developing an age-related disease, and even our risk of death.

Researchers at the School of Molecular Sciences at Arizona State University have discovered a potential way to supercharge our stem cells and reverse some aspects of cellular aging.

The Hayflick limit

Normal cells cannot divide indefinitely; they have a built-in replicative limit, which is often called the Hayflick limit after its discoverer, Leonard Hayflick. This Hayflick limit means that regular human cells are unable to replicate forever; once they reach their replicative limit, they cease to divide and enter senescence, a nondividing state in which the cell destroys itself.